[1] Nelson DR.. Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution [J]. Archives of Biochemistry and Biophysics 2003, 1(1).
[2] LARSON J R, COOM M J, PORTER T D. Purification and properties of a shortened form of cytochrome P450 2E1:Deletion of the NH2-terminal membrane insertion signal peptide does not alter the catalytic activities [J]. Proceedings of the National Academy of Sciences of the United States of America 1991, 88.
[3] BARNES H J, ARLOTTO M P, WATERMAN M R. Expression and enzymatic activity of recombinant cytochrome P450 17-hydroxylase in Escherichia coli [J]. Proceedings of the National Academy of Sciences of the United States of America 1991, 88.
[4] SUEYOSHI T, PARK L J. Molecular engineering of microsomal CYP 2a-4 to a stable, watersoluble enzyme [J]. Archives of Biochemistry and Biophysics 1995, 322(10).
[5] WADA A, MATHEW P A, BARNES H J. Expression of functional bovine cholesterol side chain cleavage cytochrome P450(P450scc) in Escherichia coli [J]. Archives of Biochemistry and Biophysics 1991, 290(02).
[6] SAKAKI K, OEDA K. Monooxygenase activity of Saccharomyces cerevisiae cells transformed with expression plasmids carrying rat cytochrome P-450MC cDNA [J]. Journal of Biochemistry 1986, 99(03).
[7] GONZLEZ F J, KORZEKWA K R. Cytochromes expression systems [J]. Annual Review of Pharmacology and Toxicology 1995, 35(04).
[8] Toshiyuki Sakaki, Kuniyo Inouye. Practical Application of mammalian Cytochrome P450 [J]. Journal of Bioscience and Bioengineering 2000, 6(6).
[9] PEYRONNEAU M A, RENAUD J P. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5 [J]. European Journal of Biochemistry 1992, 207(01).
[10] ALAIN H, MARC M, DANIELE W. Partial recoding of P450 and P450 Reductase cDNAs for improved expression in yeast and plants [J]. Methods in Enzymology 2002, 357(04).
[11] Masimirembwa CM, Otter C, Berg M, Jonsson M, Leidvik B, Jonsson E, Johansson T, Backman A, Edlund A, Andersson TB. Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. [J]. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1999, 10(10).
[12] GROGAN J, SHOU M G, ANDRUSIAK E A. Cytochrome P450 2A1, 2E1, and 2C9 cDNA-expression by insect cells and partial purification using hydrophobic chromatography [J]. Biochemical Pharmacology 1995, 50(09).
[13] Sawada M, Kamataki T. Genetically engineered cells stably expressing cytochrome P450 and their application to mutagen assays. [J]. Mutation Research: International Journal on Mutagenesis, Chromosome Breakage and Related Subjects 1998, 1(1).
[14] Shimada T, Tsumura F, Yamazaki H. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. [J]. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1999, 11(11).
[15] Bort R, Mace K, Boobis A, Gomez Lechon-MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. [J]. Biochemical Pharmacology 1999, 5(5).
[16] IRINA E K, EUGENE Y. Transgenic yeast expressing human cytochrome P450s can serve as a tool in studies of the mechanisms of their induction by various effectors [J]. Biochemical and Biophysical Research Communications 1996, 221(01). |
